Table 3.
Effect of the tested drugs on mean blood pressure in alloxan-induced diabetic rats
| Mean Blood Pressure MBP (mmHg) | ||||
|---|---|---|---|---|
| Groups | Week 1 | Week 2 | Week 3 | Week 4 |
| Normal control group | 110 ± 4.01 | 118.25 ± 8.99 | 108.75 ± 4.57 | 111.5 ± 4.20 |
| Diabetic control group | 112.5 ± 9.14 | 121.75 ± 11.35 | 150.75 ± 5.25* | 151.25 ± 5.12* |
| Diabetic group treated with bromocriptine | 115 ± 9.12 | 102.75 ± 6.8 | 109 ± 10.23# | 121.75 ± 15.26# |
| Diabetic group treated with cabergoline | 103.75 ± 7.0 | 105.5 ± 9.14 | 123 ± 7.87# | 107.75 ± 107.75# |
| Diabetic group treated with sarpogrelate | 118.75 ± 10.87 | 114.75 ± 8.53 | 137.75 ± 8.53 | 139 ± 18.56 |
| Diabetic group treated with bromocriptine + sarpogrelate | 104.5 ± 7.59 | 104.75 ± 4.99 | 106.25 ± 11.08# | 118 ± 13.03# |
| Diabetic group treated with cabergoline + sarpogrelate | 109.25 ± 11.58 | 105 ± 9.05 | 106 ± 18.3# | 104.25 ± 5.5# |
Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from the normal control group; # P < 0.05, significantly different from the diabetic control group